Agios Pharmaceuticals, Inc. (AGIO)
37.00
-0.19
(-0.51%)
USD |
NASDAQ |
Oct 23, 16:00
37.00
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Enterprise Value : 1.619B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.619B |
| October 22, 2026 | 1.630B |
| October 21, 2026 | 1.630B |
| October 20, 2026 | 1.598B |
| October 19, 2026 | 1.494B |
| October 16, 2026 | 1.280B |
| October 15, 2026 | 1.340B |
| October 14, 2026 | 1.260B |
| October 13, 2026 | 1.214B |
| October 12, 2026 | 1.251B |
| October 09, 2026 | 1.310B |
| October 08, 2026 | 1.316B |
| October 07, 2026 | 1.308B |
| October 06, 2026 | 1.304B |
| October 05, 2026 | 1.276B |
| October 02, 2026 | 1.309B |
| October 01, 2026 | 1.350B |
| September 30, 2026 | 1.395B |
| September 29, 2026 | 1.398B |
| September 28, 2026 | 1.406B |
| September 25, 2026 | 1.356B |
| September 24, 2026 | 1.375B |
| September 23, 2026 | 1.451B |
| September 22, 2026 | 1.498B |
| September 21, 2026 | 1.437B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.385B |
| September 17, 2026 | 1.417B |
| September 16, 2026 | 1.378B |
| September 15, 2026 | 1.369B |
| September 14, 2026 | 1.394B |
| September 11, 2026 | 1.416B |
| September 10, 2026 | 1.419B |
| September 09, 2026 | 1.478B |
| September 08, 2026 | 1.413B |
| September 04, 2026 | 1.387B |
| September 03, 2026 | 1.388B |
| September 02, 2026 | 1.448B |
| September 01, 2026 | 1.453B |
| August 31, 2026 | 1.421B |
| August 28, 2026 | 1.400B |
| August 27, 2026 | 1.457B |
| August 26, 2026 | 1.440B |
| August 25, 2026 | 1.434B |
| August 24, 2026 | 1.359B |
| August 21, 2026 | 1.386B |
| August 20, 2026 | 1.418B |
| August 19, 2026 | 1.507B |
| August 18, 2026 | 1.464B |
| August 17, 2026 | 1.418B |
| August 14, 2026 | 1.414B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Biogen, Inc. | 44.10B |
| Insmed, Inc. | 19.97B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -100.70M |
| Revenue (Quarterly) | 44.74M |
| Total Expenses (Quarterly) | 145.45M |
| EPS Diluted (Quarterly) | -1.693 |
| Gross Profit Margin (Quarterly) | 90.29% |
| Profit Margin (Quarterly) | -225.1% |
| Earnings Yield | -18.95% |
| Normalized Earnings Yield | -18.95 |